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Abstract 
First transcatheter embolization of hepatic artery has been materializing in 1974, in France, for unresectable 
hepatic tumours. Then, this treatment has become use enough in many countries, especially in Japan, where primary 
hepatic tumours are very frequent. 
In this article, we present procedures of interventional endovascular treatment for primary hepatic tumours: 
chemoembolization, intra-arterial chemotherapy. 
The study comprises patients with primary hepatic tumours investigated by hepatic-ultrasound and contrast-
enhanced CT or MRI. DSA-hepatic angiography is very important to verify the accessory hepatic supply. It has been 
performed selective catheterization of right/left hepatic branches followed by cytostatics injection. Most of the patients 
have benefit by hepatic chemoembolization (cytostatics, Lipiodol and embolic materials). The selective intra-arterial 
chemotherapy (cytostatics without Lipiodol) was performing in cases with contraindications for Lipiodol or embolic 
materials  injection  (cirrhosis-Child  C,  thrombosis  of  portal  vein,  hepatic  insufficiency).  For  treatment  of  primary 
hepatic  tumours  we  use  5-F-Uracil,  Farmarubicin  and  Mytomicin  C.  Less  numbers  of  the  reservoirs  were  placed 
because financial causes. 
Chemoembolization was better than procedures without Lipiodol or embolic materials. Lipiodol reached in 
tumoural  tissue  and  the  distribution  of  Lipiodol  harmonises  with  degree  of  vascularisation.  After  the 
chemoembolization procedure, the diameter of tumours decreased gradually depending on the size of tumour. 
Effective alternative for unresectable primary hepatic tumours (big size, hepatic dysfunction, and other surgical 
risk factors) is endovascular interventional treatment. 
 
Introduction 
 
Hepatocellular carcinoma is the most frequent primary hepatic  tumour with an incidence 
between 80% and 90%. This type of cancer is discovered six to eight times more frequent in men 
with the greatest risk of appearance from sixth to eighth decade in regions with low incidence but it 
may  appear  between  thirty  to  forty  years  in  populations  where  hepatocellular  carcinoma  has  a 
higher incidence [1, 14]. 
A  series  of  factors  favour  the  appearance  of  hepatocellular  carcinoma,  hepatic  cirrhosis 
being the most important. 
The growing incidence of HBV and HCV infections increased the number of hepatocellular 
carcinoma associated with viral cirrhosis. Also, alcoholic cirrhosis, more frequent in our country, 
present a certain malignant risk, based on the carcinogenic effect of alcohol. Another risk factors 
responsible for hepatocellular carcinoma are Aflatoxin B1 (a product of a mould called Aspergillus 
flavus), hemochromatosis, Wilson disease or thyrosinemia [8, 9]. 
Usually, patients with hepatocellular carcinoma have an atypical simptomathology. Several 
patients  may  present  diffuse  abdominal  pain,  loss  of  appetite,  bloating,  asthenia  or  cirrhotic 
symptoms; viral infection is diagnosed in the same time with primitive tumour in most of the cases. 
 
Screening 
 
For the early diagnosis of small (under 2 cm) and asymptomatic hepatocellular carcinoma, 
screening of patients with chronic hepatic disease has been made with the aid of ultrasonography 
and the blood values of alfa-fetoprotein, HBV and HCV markers determined on every three months 
(Fig 1) [12]. Journal of Medicine and Life  Vol. 1, No.4, October-December 2008 
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SCREENING ALGORITHM FOR  SCREENING ALGORITHM FOR 
HEPATOCELLULAR CARCINOMAS DEVELOPED  HEPATOCELLULAR CARCINOMAS DEVELOPED 
ON VIRAL ETHIOLOGY CIRRHOTIC LIVER ON VIRAL ETHIOLOGY CIRRHOTIC LIVER
SCREENING SCREENING
- - US US / 3 / 3- -4  4 months months
- - AFP / 3 AFP / 3- -4  4 months months
- - CT  CT / / 6 6- -12  12 months months
NEGATIVE NEGATIVE
Positive  Positive 
diagnosis diagnosis
<2cm <2cm
Optional: Optional:
- - IRM IRM
- - DSA/CTAP DSA/CTAP
- - Biopsy Biopsy
>2cm >2cm
Evaluation: Evaluation:
size size
vascularity vascularity
histology histology
Treatment Treatment
 
Fig 1. Hepatocellular carcinoma screening algorithm 
Abdominal ultrasonography is the first intention diagnostic method and it has been used also 
for monthly evaluation of endovascular treatment. Early hepatocellular carcinoma presents as an 
unique or multiple nodular tumour with relative well defined borders, parenchyma consistency and 
hipoechogenic.  HCC  presents  unhomogenous  echographic  structure  and  rarely  intratumoral 
calcifications.  Ultrasonography  may  also  discover  portal  trunk  or  branches  thrombosis  (often 
associated with hepatocarcinoma). 
Later  on,  primitive  tumours  smaller  than  2  cm  discovered  by  ultrasonography  will  be 
evaluated by abdominal CT. In the areas with high incidence of viral hepatitis, abdominal CT is 
recommended  every  6  to  12  months  even  if  the  echography  is  negative  [1,12].  On  native 
examination, hepatocellular carcinoma presents as a hypodense (in the majority of the cases) or 
isodense mass with central hypodense (zones or necrosis or fatty liver) or hyperdense areas (recent 
tumoral  haemorrhages).  In  the  arterial  phase  of  the  contrast  injection  CT,  HCC  is  shown  as  a 
hiperdense  mass  with  rapid  wash-out  while  in  the  venous  phase  in  appears  hypodense  with 
hiperdense capsule and septa. IRM may be used for the diagnosis of hepatic tumour in patients with 
cirrhotic liver and regenerative nodules and also in patients whose ultrasonographic exam diagnosed 
hepatomas larger than 2 cm. 
Selective hepatic angiography is used to confirm the diagnosis of hepatic tumour, to better 
visualize the hepatic arterial vessels, to discover eventual arterial-portal shunts and also to decide 
which  type  of  endovascular  treatment  protocol  should  be  followed  (chemoembolisation,  i.e. 
chemotherapy or subcutaneous reservoir implantation). Along with a selective hepatic arteriography, 
an angiography of the celiac trunk is necessary to determine the eventual presence of a tumoral 
extra-vascularisation (branches from left-gastric, gastro-duodenal or phrenic arteries) or the superior 
mesenteric arteriography in order to visualize the possible origin of the right hepatic artery from the 
proximal part of the superior mesenteric artery [2, 3]. Journal of Medicine and Life  Vol. 1, No.4, October-December 2008 
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Treatment  
 
The treatment algorithm should always be decided following  important data such as  the 
clinical  status  of  the  patient,  the  hepatic  dysfunction  degree  or  the  tumours’  number,  size  and 
location (Fig. 2). 
 
Treatment algorithm Treatment algorithm
HCC HCC
A, B A, B C C
Hepatic disfunction 
degree
Hepatic disfunction  Hepatic disfunction 
degree degree
Number Number 1 1 4 < 4 < 2  2 - - 3 3 1  1 - - 3 3 4 < 4 <
Size  Size  < 3cm < 3cm 3cm < 3cm <
Rezection Rezection Transplant Transplant
< 3cm < 3cm
RFA RFA RFA* RFA*
*HCC<2cm
Without vascular 
invasion
*HCC<2cm
Without vascular 
invasion
TACE TACE
Palliative  Palliative 
treatment treatment
 
 
Fig. 2 Hepatomas treatment algorithm 
 
Endovascular treatment is mandatory for several situations: 
1.  Unresectable tumours: multiple tumours, tumours greater than 8 cm, vascular invasion 
or tumours situated too close to major hepatic vessels. 
2.  First two Okuda stage hepatic cirrhosis associated with tumours between 4 cm and 8 cm 
in diameter [4, 5]. 
3.  Tumours  smaller  than  4  cm  in  diameter  in  which  radiofrequency  ablation  was 
contraindicated 
4.  Anesthetic or surgical risks.  
Case 1 
67  years-old  patient,  without  any  personal  pathology,  presents  to  the  hospital  having 
unspecific  simptomathology  such  as  fatigue,  inapetency  or  right  upper  quadrant  pain.  The 
ultrasonography describes a cirrhotic liver which presents in the sixth segment a hipoechogenic, 
unhomogenous  tumour  of  51mm  in  diameter.  Later  on,  the  diagnosis  is  sustained  by  the  IRM 
findings (Fig. 3), the high levels of alfa-fetoprotein and the presence of hepatitis B. 
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Fig. 3 Primitive tumor on cirrhotic liver with hepatitis B 
The diagnostic arteriography described a hipervascular, unhomogenous, septated, relatively 
well  defined  tumour,  irrigated  from  a  segmentary  branch  of  the  right  hepatic  artery  (Fig.  4.). 
Superior mesenteric arteriography confirms the permeability of the portal vein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4 Diagnostic arteriography Journal of Medicine and Life  Vol. 1, No.4, October-December 2008 
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Following the treatment algorithm, is decided that intra-arterial chemo-embolisation is the 
most suitable treatment method for our case, consisting of monthly sessions of 1 hour perfusion 
with  5-Fluoro-Uracil 750mg  followed  by  a  mixture  between  Farmarubicin  50mg, Mytomicin C 
15mg and Lipiodol. The arterial branch irrigating the tumour was than occluded with TachoComb. 
After the first chemoembolisation, arteriography showed the absence of contrast inside the tumour 
while the vascular branch still being permeable. 
During intervention, the patient presented mild epigastric pain, remitted after ingestion of 
analgesics. Other post-chemoembolisation symptoms were nausea and fever. 
After 9 chemoembolisation sessions the AFP was normal and the CT described that the 
tumour decreased its activity and reduced its dimensions by thirty percent (Fig. 6), situation also 
confirmed by the arteriography (Fig 5). 
 
 
 
Fig. 5 DSA - 9 months post-embolisation 
 
 
Fig. 6 CT - 9 months post-embolisation Journal of Medicine and Life  Vol. 1, No.4, October-December 2008 
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Case II 
56  years-old  patient,  diagnosed  3  years  ago  with  hepatitis  C,  third  degree  oesophageal 
varices, following a four months ultrasonographic screening, is diagnosed with hepatoma situated in 
the fifth hepatic segment. 
Abdominal CT and angiography confirmed the echographic diagnosis (Fig. 7). Because of 
the  decompensate  cirrhosis  and  the  surgical  risks,  tumour  resection  is  contraindicated,  so  it’s 
decided  that  the  best  treatment  solution  for  our  patient  is  monthly  hepatic  chemoembolisation 
sessions  with  5-Fluoro-Uracil  750mg,  Farmarubicin  50mg,  Mytomicin  C  15mg,  Lipiodol  and 
TachoComb. Fortunately, the patient hasn’t developed any post-embolisation syndrome. 
 
 
 
Fig. 7 Pre-embolisation DSA 
 
After 12 sessions of hepatic chemoembolisation, the arteriography determined high Lipiodol 
persistency inside the tumour and the lack of contrast-enhancing at this level (Fig.  8); CT also 
determined complete tumour necrosis (Fig. 8). 
 
 
Fig. 8 12 months post- embolisation DSA Journal of Medicine and Life  Vol. 1, No.4, October-December 2008 
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Discussions 
In the absence of an adequate treatment, the rate of survival in patients with hepatoma is 
several months (maximum 10 months). The most frequent causes of death are cachexia, gastro-
intestinal  bleeding,  hepatic  insufficiency,  and  in  a  small  number  of  cases,  spontaneous  tumour 
rupture [6]. 
The most important prognostic factors are: number, size and location of hepatic tumours, 
portal vein thrombosis, cirrhosis and restant hepatic parenchyma dysfunction degree [7]. 
Hepatic transplant and hepatic resection are still the only curative methods of treatment. 
After tumour resection, the 5 year survival rate is 25 to 30% but in careful selected patients, it can 
reach 50%. [13, 15]. 
Chemoembolisation  results  are  evaluated  determining  size,  location  and  local  tumour 
extends; very important is also the degree of hepatic failure (based on Child-Pugh classification). 
Patients from Child C group have a low survival rate because of the important hepatic dysfunction 
[10].  On  patients  who  underwent  surgery,  the  5  year  survival  rate  is  higher  than  post-
chemoembolisation (38% compared to 80%), especially when resected tumours were unique and 
smaller than 2 cm. 
Referring  to  Child  classification  regarding  the  hepatic  reserve,  the  chemoembolisation 
survival rate is higher than the one obtained after palliative, non-curative surgical intervention, on 
Child A patients [9, 11]. 
Regarding both palliative nature of interventional gesture and malignity of hepatic lesions, 
the overall prognosis remains reserved. 
Nowadays,  hepatic  chemoembolisation  is  a  modern  endovascular  treatment  method  of 
hepatomas developed on cirrhotic liver. For unresectable tumours with absolute contraindication for 
radiofrequency ablation, hepatic chemoembolisation remains the only method of treatment. 
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